2020, Number 276
Chloroquine and Hydroxychloroquine in the treatment of the COVID-19
Full text
Language: Spanish
References: 7
Page: 1-1
PDF size: 207.12 Kb.
Text Extraction
No abstract.REFERENCES
Gautret P, Lagier LC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of anopen-label non-randomized clinical trial, International Journal of Antimicrobial Agents [Internet]. 2020 [citado 23 de junio 2020]; 59(1): 1-24. Disponible en: https://doi.org/10.1016/j.ijantimicag.2020.105949.
La cloroquina y la hidroxicloroquina aumentan el riesgo de muerte en pacientes con coronavirus. INFOMED [Internet]. La Habana: ECIMED; 1992 [actualizado 23 de mayo 2020; citado 22 de junio 2020. Disponible en: http://www.sld.cu/node?iwp_post=2020%2F05%2F25%2FLa%20cloroquina%20y%20la%20hidroxicloroquina%20aumentan%20el%20riesgo%20de%20muerte%20en%20pacientes%20con%20coronavirus%2F184103&iwp_
Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin G, et al. ‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies [Internet]. 2020 [citado 23 de junio 2020]; 45(3): 1-9. Disponible en: https://doi.org/10.1016/j.therap.2020.05.002
Silva MG, Almeida FF, Sousa V, Araújo MA, Cardoso G, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study).MedRxiv [Internet]. 2020 [citado 23 de junio 2020]; 24(1): 1-31 Disponible en https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1.full.pdf.